Drug
EB Dart Nk01
EB Dart Nk01: highest development phase Phase 1/2, developed by Beijing Biotech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Beijing Biotech
Trials
| Drug | Phase | Indication |
|---|---|---|
| EB-DART-NK01 (DLL3/CD56 CAR-NK cells) NCT07480213 | Phase 1/2 | Small Cell Lung Cancer (SCLC) |
Latest
No recent events.
Follow EB Dart Nk01 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.